Why your drug-plan premium has felt steady

If you buy a stand-alone Part D drug plan and your premium has felt unusually steady the past couple of years, there is a reason that is easy to miss, and worth understanding before you shop this fall. Since 2025, Medicare has run a voluntary Part D Premium Stabilization Demonstration. In plain terms, the government has been paying to soften how much stand-alone drug-plan premiums can swing from one year to the next, so the market did not lurch as the big Inflation Reduction Act drug changes took effect. Nearly every drug-plan sponsor signed up. The catch is in the design: the cushion is deliberately shrinking each year. For 2025, the program lowered the base beneficiary premium by up to $15 and capped how much any single plan's premium could rise at $35. For 2026, that base reduction was trimmed from $15 to $10 and the cap on premium increases was loosened from $35 to $50. The demonstration was planned to run three years, through 2027, which is its final scheduled year, with the support continuing to taper. None of this is cause for alarm, and it is not a reason to switch plans on its own. It is a reason to actually read your plan's Annual Notice of Change when it arrives in the fall and to compare, rather than assume your premium will hold simply because it did last year. The number that has been partly propped up is allowed to move more as the program winds down, and that can vary a lot from one plan to the next. The same advice that always applies applies here with a little more force this year: at Annual Enrollment, look at the full picture, the premium, the deductible, and what your specific drugs cost under each plan, not just the premium line. The pointed framing about whether the government should have to subsidize premiums at all routes to my65checklist; here the point is simply to know the cushion is thinner and to shop with eyes open.